Several mutations were identi®ed in the kinase domain of the RET proto-oncogene in patients with multiple endocrine neoplasia (MEN) 2B, familial medullary thyroid carcinoma (FMTC) or sporadic medullary thyroid carcinoma. We introduced seven mutations (glutamic acid 768?aspartic acid (E768D), valine 804?leucine (V804L), alanine 883?phenylalanine (A883F), serine 891?alanine (S891A), methionine 918 ?threonine (M918T), alanine 919?proline (A919P) and E768D/A919P) into the short and long isoforms of RET cDNA and transfected the mutant cDNAs into NIH3T3 cells. The transforming activity of the long isoform of Ret with each mutation was much higher that that of its short isoform. Based on the levels of the transforming activity, these mutant RET genes were classi®ed into two groups; a group with high transforming activity (A883F, M918T and E768D/A919P) and a group with low transforming activity (E768D, V804L, S891A and A919P) (designated high group and low group). Interestingly, the level of transforming activity correlated with clinical phenotypes; high group Ret with the A883F or M918T mutation and low group Ret with the E768D, V804L or S891A mutation were associated with the development of MEN 2B and FMTC, respectively. In addition, we found that substitution of phenylalanine for tyrosine 905 present in the kinase domain abolished both transforming and autophosphorylation activities of low group Ret whereas it did not aect the activities of high group Ret. (cysteines 609, 611, 618, 620, 630 and 634) in the extracellular domain of Ret (Mulligan et al., 1993 (Mulligan et al., , 1994 Donis-Keller et al., 1993; Lips et al., 1994; Eng et al., 1996), whereas a point mutation (methionine 918?threonine, M918T) in the tyrosine kinase domain was detected in MEN 2B (Hofstra et al., 1994; Carlson et al., 1994). We and others demonstrated that MEN 2A, MEN 2B and FMTC mutations represent gain-of-function mutations (Santoro et al
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Several other mutations in the kinase domain have recently been identi®ed in MEN 2A, MEN 2B, FMTC and sporadic MTC patients. Three mutations including glutamic acid 768?aspartic acid (E768D), valine 804?leucine (V804L) and serine 891?alanine (S891A) mutations were detected in FMTC (Eng et al., 1995; Bolino et al., 1995; Hofstra et al., 1997) , and an alanine 883?phenylalanine (A883F) mutation in MEN 2B and sporadic MTC Gimm et al., 1997) . In addition, an E768D/A919P double mutation was found in metastatic lymph nodes from a Japanese female FMTC patient (Miyauchi et al., 1997) . Except for Ret with the E768D or V804L mutation , there is no information about the mechanism of activation of Ret with newly identi®ed kinase domain mutations. To understand the molecular mechanisms of its activation by these mutations, we investigated biological and biochemical properties of mutant Ret proteins.
As shown in Figure 1 , E768 and V804 are located in the kinase domain 1 and A883, S891, M918 and A919 exist in the kinase domain 2. Since it is known that Ret is translated mainly as two isoforms of 1072 (short isoform) and 1114 (long isoform) amino acids that dier from each other in the carboxyl-terminal sequence ( Figure 1 ) (Tahira et al., 1990) , we introduced these mutations into RET cDNA encoding each isoform and compared the transforming activity of the mutant cDNAs by transfection of NIH3T3 cells.
In addition, the activity of Ret with an E768D/A919P double mutation that was found in metastatic foci of a Japanese female FMTC patient was examined. We previously reported that the transforming activity of the long isoform with the M918T mutation was approximately tenfold higher than that of its short isoform whereas the transforming activity of the long isoform with the MEN 2A (C634R) mutation was 1.5-fold higher than that of its short isoform (Asai et al., 1995 (Asai et al., , 1996 Iwashita et al., 1996) . As observed for Ret with the M918T mutation, the transforming activity of the long isoform with kinase domain mutations examined in this study was much higher (more than ®vefold) than that of their short isoform (Figure 2 ). In particular, the transforming activity of the short isoform with the E768D, V804L or A919P mutation was almost undetectable (Figure 2 ).
We also found that the transforming activity of the long isoform with the A883F, M918T or E768D/ A919P mutation was 10 ± 15-fold higher than that of the long isoform of Ret with the E768D, V804L or A919P mutation (Figure 2 ). The transforming activity of the long isoform with the S891A mutation was about 2 ± 3-fold higher than that of the long isoform with the E768D, V804L or A919P mutation. Based on the levels of the transforming activity of the long isoform, the mutations detected in the kinase domain were classi®ed into two groups, a group with high transforming activity (A883F, M918T and E768D/ A919P, designated high group) and a group with low transforming activity (E768D, V804L, S891A and A919P, designated low group) (Figure 2) . Interestingly, it turned out that two mutations of high group (A883F and M918T) and three mutations of low group (E768D, V804L and S891A) were associated with the development of MEN 2B and FMTC, respectively. In addition, high transforming activity of Ret with the E768D/A919P mutation found in a Japanese FMTC patient appeared to correlate with malignant progression of tumor cells. CAD, cadherin-like domain; CYS, cysteine-rich region; TM, transmembrane domain; TK, tyrosine kinase domain; aa, amino acids. One cysteine mutation (C634R) in the extracellular domain and six mutations (E768D, V804L, A883F, S891A, M918T and A919P) in the kinase domain analysed in this study are shown. Y905 and Y1062 are tyrosine residues that were replaced with phenylalanine. The short isoform (1072 amino acids) and long isoform (1114 amino acids) dier from each other in the carboxyl-terminal sequence. These two isoforms are generated by alternative splicing in the 3' region of the RET gene (Tahira et al., 1990) Figure 2 Transforming activity of the mutant RET genes. A cDNA clone containing the entire coding sequence (for 1072 or 1114 amino acids) of the human RET gene was inserted into the vector containing the Moloney murine leukemia virus long terminal repeat. Each mutation was introduced by polymerase chain reaction. Each plasmid DNA (0.1 ± 0.4 mg) was transfected into NIH3T3 cells (5610 5 cells in a 60 mmdiameter dish) with 0.04 mg of pSV2neo plasmid DNA and 10 mg of NIH3T3 genomic DNA as described previously (Asai et al., 1995) . Transformed foci were scored on day 12 after transfection. Transforming activity of the short (white bars) and long (black bars) isoforms of the designated mutant Ret proteins is shown. Transforming activity of both isoforms of wild type RET was almost undetectable. Two independent experiments were performed for each mutant RET gene Figure 3 Expression and tyrosine phosphorylation of the mutant Ret proteins. The transfectants expressing the designated mutant proteins were suspended in sodium dodecyl sulfate (SDS)-sample buer (20 mM Tris-HC1, pH 7.5, 2 mM EDTA, 2% SDS, 10% sucrose, 10 mM iodoacetamide, 20 mg/ml bromophenol blue) in the presence (reducing) (a, b) or absence (non-reducing) (c) of 80 mM dithiothreitol. The resulting total lysates were subjected to SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene di¯uoride membranes (Nihon Millipore Kogyo KK, Tokyo, Japan). After anti-Ret antibody (a, c) or antiphosphotyrosine antibody (4G10) (Zymed Laboratories, Inc., South San Francisco, CA, USA) (b) was used as the ®rst antibody, the reaction was examined as described previously (Nozaki et al., 1998) . The 155 kDa and 175 kDa Ret monomers and 350 kDa Ret dimers are indicated NIH3T3 cells expressing the long isoform with each kinase domain mutation were established ( Figure 3a) . As described previously (Asai et al., 1995; Iwashita et al., 1996; Ito et al., 1997) , Ret is expressed as the 155 kDa and 175 kDa proteins that correspond to the immature glycosylated form present in the cytoplasmic membrane fraction and the mature glycosylated form at the plasma membrane, respectively. The patterns of tyrosine phosphorylation of mutant Ret proteins were similar among the established cell lines. The 175 kDa Ret protein with each mutation was more highly phosphorylated than the 155 kDa Ret protein ( Figure  3b ). Despite the dierence of their transforming activity, the reason why the level of tyrosine phosphorylation of each mutant Ret protein was almost equal is currently unclear. Western blot analysis under non-reducing conditions revealed that, unlike Ret with the C634R (MEN 2A) mutation (Asai et al., 1995) , the dimer formation of the 175 kDa Ret form with kinase domain mutations was undetectable (Figure 3c ).
We previously found that tyrosine residues in the kinase domain essential for the transforming activity are dierent between Ret with the MEN 2A (C634R) mutation and Ret with the MEN 2B (M918T) mutation. Substitution of phenylalanine for tyrosine 905 (Y905F) completely abolished the transforming activity of Ret-MEN2A (C634R) but not Ret-MEN2B (M918T) (Iwashita et al., 1996) . This tyrosine is known to be conserved in all tyrosine kinases and play crucial roles in their catalytic and/or biological activities. As shown in Figure 4a , the transforming activity of high group Ret was not aected by replacing tyrosine 905 with phenylalanine (Y905F). Consistent with this observation, tyrosine phosphorylation of high group Ret with the Y905F mutation did not signi®cantly decrease (Figure 5a and b) . In contrast, the transforming activity and tyrosine phosphorylation of low group Ret were abolished by the Y905F mutation (Figures 4b, 5c and d) , indicating that this tyrosine residue plays a crucial role in the activities of low group Ret.
We also reported that binding of the Shc PTB domain to tyrosine 1062 in the Ret long isoform is important for the transforming activity of Ret with the C634R or M918T mutation (Asai et al., 1996; Lorenzo et al., 1997; Arighi et al., 1997; Durick et al., 1998) . As shown in Figure 4 , when tyrosine 1062 in Ret with each kinase domain mutation was replaced with phenylalanine, the transforming activity of the mutant proteins markedly decreased, suggesting the importance of the binding of the Shc PTB domain to tyrosine 1062 for their transforming activity.
Based on the results of the present study, we propose three dierent activation mechanisms of the mutant Ret proteins, leading to the development of MEN 2A, MEN 2B and FMTC. First, cysteine mutations found in the extracellular domain induce ligand-independent Ret dimerization and result in the /A919P ). In addition, the integrity of tyrosine 905 is not required for the transforming activity and autophosphorylation of Ret with these mutations. Third, Ret with three other kinase domain mutations (E768D, V804L and S891A) has low transforming activity and is associated with the development of FMTC. Tyrosine 905 is a key residue for both transforming activity and autophos-phorylation of these mutant proteins.
